Skip to Main Content

A drug from Amgen designed to block the cancer protein known as KRAS shrank tumors in 37% of patients with advanced lung cancer and delayed tumor progression by just under seven months, according to results from a clinical trial announced Thursday.

The Amgen drug, a pill called sotorasib, is the most important medicine in Amgen’s cancer research pipeline. It’s being tracked closely by researchers and investors because of its potential to attack certain cancer cells with a genetic mutation that was previously thought to be unreachable.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED